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Protocols for blocking non-specific antibody (Ab) binding in immunohistochemistry are 
based on rather contradictory and outdated reports.  This prompted us to prove, 
whether non-specific Ab binding may really lead to unwanted background staining in 
routinely processed cell and tissue probes.  In this study, the probes were fixed and 
processed according to routine protocols with and without blocking step (goat serum or 
BSA).  Surprisingly, all Ab in probes processed without blocking step did not show any 
propensity to non-specific binding that might lead to background staining, thus implying 
that endogenous Fc receptors do not retain their ability to bind Fc portion of Ab after 
standard fixation.  Likewise in routinely fixed probes, we did not found any non-specific 
Ab binding ascribed to a combination of ionic and hydrophobic interactions.  The 
traditionally used protein blocking step is useless in immunostaining of routinely fixed 
cell and tissue probes.   
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The causes of non-specific background immunostaining might be different, but they have one 
thing in common: they may complicate the use of immunohistochemistry.  Whereas unwanted 
background staining due to endogenous enzyme activities or endogenous biotin is no more a 
problem in contemporary immunohistochemistry, nonspecific antibody (Ab) binding leading 
to unwanted background staining remains subject to considerable debate.  Among the possible 
causes of non-specific binding of Ab, attraction of primary and/or secondary Ab to 
endogenous Fc receptors (FcRs) was supposed to be the main source of unwanted staining.   
FcRs are structures on the surface of certain cells, which bind the Fc region of Ab.  
They provide an important link between cellular and humoral branches of the immune system 
by triggering several immune responses including phagocytosis, endocytosis, antibody-
dependent cytotoxicity, release of inflammatory mediators, and enhancement of antigen 
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presentation1.  The nature of responses depends primarily on the cell type on which these 
FcRs are expressed.  There are several different types of FcRs; they are classified based on the 
type of immunoglobulins that they recognize2.  FcRs for immunoglobulins G (IgG) - the most 
common class of Ab used in immunohistochemistry – are designated Fc-gamma receptors 
(FcγR).  Other FcRs are expressed on multiple cell types and are similar in structure to MHC 
class I.  This receptor is involved in preservation of antibodies and also binds IgG3.   
It was theorized that FcRs can bind Fc region of Ab not only in vivo but also in 
immunohistochemical assays of cell and tissue samples.  This concept is picked up over and 
over again in numerous publications, but we were unable to find out the original resource.  
Since its inception half a century ago, this concept is being entertained in all reviews and 
handbooks on immunohistochemistry4-7.  According to this concept, preincubation with with 
5-10% normal serum from the host species of the secondary Ab should prevent non-specific 
Ab binding to endogenous FcRs.  Curiously, this is totally senseless in immunohistochemical 
assays of human probes, since the vast majority of secondary Ab used in human 
immunohistopathology come from goat and the goat (host species of the secondary Ab) serum 
was long ago reported not to bind to FcRs on human cells8.  Preincubation with solutions 
containing goat normal serum was also assumed to prevent background staining resulting 
from a combination of ionic and hydrophobic interactions5.  Blocking the non-specific 
background due to FcRs or due to a combination of ionic and hydrophobic interactions is 
regarded as an obligatory step prior to incubation with primary Ab.  See 
immunohistochemical protocols in all contemporary Ab manufacturers’ catalogues (e.g., 
DIANOVA, ZytoMed, Jackson ImmunoResearch Laboratories Inc., etc.).  See also a popular 
IHC WORLD homepage (http://www.ihcworld.com/) and a homepage of the Ab 
manufacturer (Dako, Education Guide, Immunohisochemical Staining Methods, 
http://www.dako.com/de/08002_ihc_staining_methods_5ed.pdf).  All Ab manufacturers offer 
their own ready-to-use blocking solutions; in many cases their formulation is a trade secret. 
In spite of the fact that goat serum does not bind to FcRs on human cells8, goat serum 
nonetheless remains the most popular in use for FcRs blocking in human 
immunohistopathology.  Some histochemists prefer FcRs blocking with normal swine or 
rabbit serum9 without, however, providing any experimental support for their choice.  
Additionally, more complicated blocking strategies have been reported like employing 
papain-digested whole fragments of unlabeled secondary Ab enriched with Fc fragments of 
the same IgG10.  In theory, the most reasonable approach to prevent the possible non-specific 
background due to FcRs might be the use of F(ab′)2 fragments of Ab instead of the whole IgG 
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molecule11, provided that the endogenous FcRs retain their ability to bind Fc portion of IgG 
Ab after proper fixation, but that is namely the question. 
Other blocking solutions based on bovine serum albumin (BSA), coldwater-fish 
gelatin, trypton casein peptone, non-fat dry milk or casein are assumed to prevent non-specific 
background ascribed primarily to hydrophobic interactions of proteins and to ionic or 
electrostatic interactions9, 12, 13.  Casein was claimed to be more effective than normal serum 
to block hydrophobic background staining7.  However, casein, BSA and dry milk may contain 
bovine IgG14.  Many secondary Ab (i.e. anti-bovine Ig Ab, anti-goat Ig Ab, and anti-sheep Ig 
Ab) will react strongly with bovine IgG.  Therefore, use of BSA, dry milk or casein in the 
immunohistochemical protocol may significantly increase background and/or reduce antibody 
titer.  Other somewhat more complicated methods thought to reduce Ab binding to tissue 
proteins, include diluent buffers with a pH different from the pI of the Ab15; diluents with low 
ionic strength (low salt concentration) and addition of non-ionic detergents (e.g., Tween 20, 
Triton X) or ethylene glycol to the diluent16; coincubation of primary antibodies with reduced 
glutathione, L-cysteine, iodoacetic acid, Ellman's reagent and other thiophilic reagents17, 18.  
The list of recommendations of this kind can be extended, but their practicability is 
questionable and they are rarely - if any at all - used in praxis.   
Furthermore, it was not explicitly documented, whether the non-specific binding of Fc 
fragments of Ab is a problem equally for frozen and paraffin-embedded tissue sections.  On 
one hand, it was stated (no experimental support provided) that the non-specific staining due 
to attraction of Fc fragments to FcRs is more common in frozen sections than in routinely 
aldehyde-fixed paraffin-embedded tissue sections19, 20.  See also websites: 
(http://www.ihcworld.com/) and 
(http://www.dako.com/de/08002_ihc_staining_methods_5ed.pdf).  On the other hand, the 
increased hydrophobicity of proteins after aldehyde fixation and paraffin embedding was 
claimed to increase the non-specific binding of the Fc portion of IgG Ab7, 9.  Non-specific 
staining in paraffin sections was also alleged to happen because of attraction of the Fc portion 
of IgG Ab to basic groups present in collagen fibers21.   
 Taken together, the reports about the possible background immunohistochemical 
staining due to the non-specific Ab binding in frozen and paraffin-embedded tissue sections 
and in cytological preparations, are rather contradictory, most of these reports being rather 
outdated and lacking clear-cut experimental support.  This prompted us to prove, whether the 
commercially available Ab do have a propensity to random non-specific binding in 
imunolabeling of routinely fixed cell and tissue probes.  
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RESULTS 
In probes that were processed either with or without protein block, we did not observe any 
differences in immunostaining.  Omission of incubation with primary Ab in negative controls 
also did not led to unwanted background stainings due to anticipated non-specific binding of 
secondary Ab in probes processed without the protein blocking step, which means that the 
protein block traditionally used in immunohistochemistry does not influence the quality of 
immunostaining.   
Contrary to the speculative declaration that the unspecific background staining due to 
endogenous FcRs is more common for frozen sections and cell smears than for paraffin-
embedded tissue sections19, 20, the unspecific background staining has not appeared to be a 
problem with frozen tissue sections fixed either with formaldehyde (Fig. 1a-c) or with 
acetone, as well as with blood cell smears, cell culture monolayers and cytospins fixed in 
formaldehyde (not shown).   
Likewise, in paraffin sections of formaldehyde-fixed human tissue probes (Fig. 1d-f), 
we have not observed any background staining allegedly ascribed to the increased 
hydrophobicity of proteins after aldehyde fixation and paraffin embedding7, 9.  Contrary to the 
declaration that non-specific staining might happen in paraffin sections because of attraction 
of the Fc portion of IgG Ab to basic groups present in collagen fibers21, we did not observed 
any unspecific background immunostaining in paraffin sections of various collagen-rich 
tissues like inflammatory bone tissue (Fig. 1f), bone tissue seen in bone marrow preparations 
(Fig. 2) or media and adventitia of artery wall (not shown).   
 In view that FcRs are expressed primarily on monocytes, macrophages, B cells, 
dendritic cells, neutrophils and platelets2, we paid special attention to probes where FcRs-
bearing cells can be found abundantly - in bone marrow preparations, spleen, tonsils and 
blood cell smears.  Also in these cells, as shown with CD20 immunolabeling of human tonsils 
(Fig. 1d) and with bone marrow preparations immunostained for CD20, CD61 and CD68 
(Fig. 2), no unwanted background was observed in probes processed with omission of the 
protein block prior to incubation with primary Ab.  Likewise, no unwanted background was 
found in corresponding negative controls. This allowed us a conclusion that the endogenous 
FcRs do not retain their ability to bind Fc portion of IgG Ab after fixation routinely used in 
immunohistochemistry. 
Having performed immunostaining using fluorophore-conjugated Ab, we have also 
found that omission of the protein blocking step did not led to non-specific background 
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staining in single and multiple fluorescence immunolabeling with the use of fluorophore-
conjugated Ab or streptavidin as demonstrated here with immunofluorescent triple staining of 
cytokeratin 5, cytokeratin 10 and cytokeratin 14 in adeno-squamouse carcinoma of human 
mammary gland (Fig. 3).  
 
DISCUSSION 
During the last decades, the improvements in the reagents and protocols for 
immunohistopatholgy have led to increasing sensitivity of detection systems widely 
contributing to elimination of non-specific background immunostaining.  However, current 
protocols for blocking the unwanted background are based on rather contradictory and 
outdated reports.  The concept of attraction of Fc fragments of Ab to FcRs, as well as of non-
specific Ab binding due to hydrophobic interactions of proteins or ionic and electrostatic 
interactions, seems to reflect desperate attempts of immunohistochemists half a century ago to 
find a plausible explanation for bad immunostainings with home-made Ab that were not 
always the best quality to that time; antisera could be collected or stored in inappropriate ways 
or primary Ab could be applied in supra-optimal concentrations.  The non-specific 
background immunostaining may also result from other factors, such as inappropriate 
immunohistochemical detection method, protracted time of chromogen (e.g., DAB) 
application, improper fixative, protracted fixation time and interval before fixation.  
Maintaining of the specimen morphology during fixation is the most important prerequisite 
for good immunostaining22.  If the origin is garbage, one cannot expect wonderful results.   
The present study was performed on cryosections, cell culture monolayers, blood cell 
smears and cytospins routinely fixed not longer than 15 min in acetone or alcohol.  For 
paraffin embedding, tissue probes and bone marrow preparations were fixed in 4% buffered 
formaldehyde for 18-48 hrs (usually 24 hrs) at room temperature.  Inspection of possible 
undesirable effects of protracted fixation or the use of stronger fixation media was beyond the 
scope of this study, since the influence of fixation strength and the length of fixation on the 
availability and conformation of antigen epitopes, as well as on the maintaining of the 
specimen morphology, is generally not known, and often not predictable.  To allow proper 
evaluation and replication of immunohistochemical experiments, Ab in this study were 
applied strictly according to manufacturers’ recommendations.  Final concentration of 
primary Ab was between 1 and 5 µg/ml PBS.  Final concentration of secondary Ab was 
between 5 and 10 µg/ml PBS.  Keeping these routinized conditions, we did not observe any 
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differences in immunostaining in all probes that were processed either with or without protein 
block.  
To summarize, our data allowed us to draw the following conclusions.  The 
endogenous FcRs do not retain their ability to bind Fc portion of IgG Ab after routine fixation 
in formaldehyde, acetone or alcohol.  Likewise, non-specific Ab binding to tissue proteins 
ascribed to hydrophobic interactions of proteins or ionic and electrostatic interactions does not 
take place in routinely fixed cell and tissue probes.  In contrast to the commonly accepted 
view, the protein block traditionally used in immunohistochemistry is useless in 
immunostaining of routinely fixed cell and tissue probes. 
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METHODS  
We performed comparative immunostainings with and without protein blocking step on 
frozen and paraffin-embedded tissue sections, as well as on cell culture monolayers and 
cytospins.  For paraffin embedding, tissue probes were routinely fixed with 4% formaldehyde 
in PBS.  4 mµ-thick paraffin tissue sections were deparaffinised with xylene and graded 
ethanols, and antigen retrieval was achieved by heating the sections in 10mM sodium citrate 
buffer, pH 6.0, at 95°C x 30 min in a domestic vegetable steamer23.  Frozen tissue sections, 
cell monolayers, blood cell smears and cytospins were immunostained after fixation either 
with 4% formaldehyde, methanol or acetone.  The blocking step prior to incubation with 
primary Ab was performed with either 5-10% goat normal serum or 1% BSA in PBS.   
All Ab were applied according to manufacturers’ recommendations.  For 
immunostainings, we used 45 mouse monoclonal and rabbit polyclonal primary Ab (Table 1).  
For bright-field microscopy, bound primary Ab were detected with EnVision Horse Radish 
Peroxidase (HRP) System (DAKO Corporation, Hamburg, Germany) or with AmpliStain™ 
HRP conjugate (SDT GmbH, Baesweiler, Germany) according to manufacturers’ instructions.  
HRP label was visualized using NovaRed substrate kit (Vector Laboratories, Burlingame, CA, 
USA).  For fluorescence microscopy, we used goat secondary Ab conjugated with Cy3, Alexa 
Fluor-488, Alexa Fluor-647 or with biotin.  The latter was visualized using fluorophore-
labeled streptavidin.  Secondary system antibodies and other reagents used in this study are 
presented in Table 2.  Single and multiple immunofluorescence labeling were performed 
according to standard protocols routinely used in immunohistochemistry23.  Immunostained 
sections were examined on a Zeiss microscope “Axio Imager Z1”.  Microscopy images were 
captured using AxioCam digital microscope cameras and AxioVision image processing (Carl 
Zeiss Vision, Germany).   
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FIGURE LEGENDS  
Figure 1  Immunohistochemical staining processed without protein block prior to incubation 
with primary Ab.  Bound primary Ab were detected using DAKO EnVision+ System-HRP 
(DAKO Corporation, Hamburg, Germany) with NovaRed substrate kit (Vector Laboratories, 
Burlingame, CA, USA).  Nuclei counterstained with Ehrlich hematoxylin.  (a-c)  
Immunostaining of human tissue cryosections after routine formaldehyde fixation (3 min by 
room temperature).  (d-f)  Immunostaining of routinely formaldehyde-fixed paraffin-
embedded human tissue sections.  (a)  Immunolabeling of CD34 in capillary endothelium of 
human kidney.  (b)  Immunolabeling of cytokeratins 8/18/19 in human pancreas carcinoma.  
(c)  Immunolocalization of smooth muscle actin in arterial cell wall in human kidney.  (d)  
Immunolabeling of CD20 in B lymphocytes in human tonsil.  (e)  Immunolabeling of Glial 
Fibrillary Acidic Protein in human brain tumor astrocytoma.  (f)  Specific immunolabeling of 
collagen IV in blood vessel adventitia in inflammatory bone tissue.  Note that collagens in 
connective tissue (collagen I) and in bone (collagen I and V) do not demonstrate any affinity 
to Fc fragments of either primary or secondary Ab.   
 
Figure 2  Immunodetection of markers of Clusters of Differentiation (CD) in bone marrow 
preparations.  (a) Immunolabeling of CD20 in B lymphocytes.  (b) Immunolabeling of CD61 
in megakaryocytes and in thrombocytes.  (c) Immunolabeling of CD68 in fibroblastic 
dendritic cell and in monocytes.  Bound primary Ab were visualized using AmpliStain™ 
HRP conjugate (SDT GmbH, Baesweiler, Germany) with NovaRed substrate kit (Vector 
Laboratories, Burlingame, CA, USA).  Nuclei counterstained with Ehrlich hematoxylin.  
Immunohistochemical staining was performed without protein block prior to incubation with 
primary Ab.  Note in (a) the absence of unspecific Ab binding to bone tissue and to 
hematopoetic cells, in (b) the absence of unspecific Ab binding to granulocytes and 
monocytes and in (c) the absence of unspecific Ab binding to granulocytes and 
megakaryocytes.   
 
Figure 3  Immunofluorescent triple staining of cytokeratin 5, cytokeratin 10 and cytokeratin 
14 in adeno-squamouse carcinoma of human mammary gland.  Immunolabeling was 
performed without protein block prior to incubation with primary Ab.  (a)  
Immunolocalization of cytokeratin 14 (Alexa 488, green channel).  (b)  Immunolocalization 
of cytokeratins 10 (Cy3, red channel).  (c)  Immunolocalization of cytokeratin 5 (Alexa 647, 
pink channel).  (d)  Composite image.  Nuclei are counterstained with DAPI.   
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Table 1 Primary antibodies used in this study 
 
Antibodies Source Dilution Tissues/Cells* 
IgA (alpha), (rabbit Ab) DAKO 1/2000 1, 2, 3  
IgG (gamma), (rabbit Ab)  DAKO 1/1000 1, 2, 3 
IgM (my, µ), (rabbit Ab)  DAKO 1/1000 1, 2, 3 
Bcl2 (mouse Ab) DAKO 1/100 2, 4, 5, 6, 7 
α Smooth Muscle Actin (mouse Ab)  DAKO 1/50 4, 5, 6, 7, 8, 9 
α Smooth Muscle Actin (rabbit Ab)  AbCam 1/200 4, 5, 6, 7, 8, 9 
ApoE (rabbit Ab) Santa Cruz 1/100 10 
CD3 (mouse Ab Novocastra 1/200 2, 23 
CD10 (mouse Ab) Novocastra 1/50 5 
CD20 (mouse Ab  DAKO 1/500 2, 3, 10  
CD32 (mouse Ab) AbCam 1/1000 3, 23 
CD34 (mouse Ab) Novocastra 1/50 1, 9, 25 
CD61 (mouse Ab) Novocastra 1/100 10 
CD68 (mouse Ab) DAKO 1/200 2, 3, 10 
CD117, c-Kit (rabbit Ab) DAKO 1/100 4, 5 
Cytokeratins 5 (rabbit Ab) Medac 1/100 4, 5, 6, 7, 8, 24 
Cytokeratin 5/6 (mouse Ab) DAKO 1/50 4, 5, 6, 7, 8, 24 
Cytokeratin 7 (mouse Ab) DAKO 1/200 4, 5, 6, 7, 8, 24  
Cytokeratin 10 (mouse Ab) DAKO 1/50 4, 5, 6, 7, 13 
Cytokeratin 14 (mouse Ab) Jackson ImmunoRes 1/500 4, 5, 6, 7, 8, 24 
Cytokeratin 18 (mouse Ab) Sigma 1/50 4, 5, 6, 7, 8, 24 
Cytokeratin 8/18 (mouse Ab)  Zytomed 1/50 4, 5, 6, 7, 8, 24  
Cytokeratin AE1/AE3 (mouse Ab) DAKO 1/50 2, 4, 5, 6, 7, 13 
Cytokeratins 8/18/19 (mouse Ab) Immunotech 1/100 4, 5, 6, 7, 8 
Collagen IV (mouse Ab) DAKO 1/20 5, 11 
Desmin (mouse Ab)   DAKO 1/200 12, 25 
E-Cadherin (mouse Ab)   DAKO 1/50 1, 4, 5 
Calcitonin (rabbit Ab) DAKO 1:500 15 
Calponin (mouse Ab)   DAKO 1/50 9, 16, 17 
EMA (mouse Ab)    DAKO 1/50 1 
Estrogen Receptors (rabbit Ab) Thermo 1/200 4, 5 
GFAP (mouse Ab)    DAKO 1/100 18 
GFP (rabbit Ab) AbCam 1/500 19 
HMB45 (mouse Ab)  DAKO 1/50 13 
Kappa Light Chains (rabbit Ab) DAKO 1/8000 2, 10 
Lambda Light Chains (rabbit Ab)  DAKO 1/8000 2, 10 
Ki67 (rabbit Ab)  Thermo 1/200 2, 4, 5, 6 , 7, 24 
MIB1 (mouse Ab) DAKO 1/20 2, 4, 5, 6 , 7, 24 
Myf-4 (mouse Ab)    Zytomed 1:50 20 
nNOS (rabbit Ab) Transduction Lab.  16, 17, 21, 22 
eNOS (rabbit Ab)  Transduction Lab.  9, 16, 17, 21, 22 
P53 (mouse Ab)   DAKO 1/50 5, 7 
p63 (mouse Ab)   DAKO 1/200 4, 5, 6, 7 
S100 (rabbit Ab)   DAKO 1/2000 2, 5, 7, 10 
Vimentin (mouse Ab) DAKO 1/200 15 
Vimentin (rabbit Ab) AbCam 1/1000 5, 9 
*Probes immunostained in this study: Human kidney (1), Human tonsil (2), Human lymph nodes (3), 
Human mammary gland (4), human breast tumors (5), Human salivary gland (6), Human salivary gland 
tumors (7), Human lacrimary gland (8), Human aorta (9), Human bone marrow (10), Human bone tissue 
(11), Gastrointestinal tissue (12), Skin (13), Neonatal rat cardiomyocytes (14), Human thyroid gland (15), 
Human muscle tissue (16), Rat muscle tissue (17), Human brain astrocytoma (18), Mouse heart (19), 
Human rabdomyosarcoma (20), Human pancreas (21), Rat pancreas (22), Human blood cell smears and 
cytospins (23), Cell cultures of human adenoid cystic carcinoma (24) and of neonatal rat cardiomyocytes 
(25) 
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Table 2 Secondary antibodies and other reagents 
 
Antibodies Source Dilution Label 
Goat Normal Serum Jackson ImmunoRes 1/100 w/o 
Mouse Normal Serum Jackson ImmunoRes 1/100 w/o 
Bovine serum albumin Biomol 1% w/o 
Goat anti–mouse IgG Ab Invitrogen 1/200 Alexa 
Fluor 488 
Goat anti–mouse IgG Ab Invitrogen 1/200 Alexa 
Fluor 555 
Goat anti–mouse IgG Ab Invitrogen 1/100 Alexa 
Fluor 647 
Goat anti–rabbit IgG Ab Invitrogen 1/100 Alexa 
Fluor 647 
Biotin-SP-AffiniPure Fab Fragment 
Goat Anti-Mouse 
Jackson ImmunoRes 2-10 
µg/ml 
Biotin 
Biotin-conjugated anti-mouse IgG3 BD Pharmingen 1/25 Biotin 
Streptavidin Jackson ImmunoRes 1/200 Cy3 
Anti-mouse EnVision+ System-HRP DAKO Corporation ready-
to-use 
HRP 
Anti-rabbit EnVision+ System-HRP DAKO Corporation ready-
to-use 
HRP 
AmpliStain™ anti-Mouse 1-Step 
HRP 
SDT GmbH, Baesweiler, 
Germany 
ready-
to-use 
HRP 
AmpliStain™ anti-Rabbit 1-Step 
HRP 
SDT GmbH, Baesweiler, 
Germany 
ready-
to-use 
HRP 
4',6-diamidino-2-phenylindole 
(DAPI, nuclear counterstaining) 
Sigma 5 µg/ml w/o 
Vector® NovaRED™ Substrate Kit Vector Laboratories, 
Burlingame, CA, USA 
ready-
to-use 
w/o 
VECTASHIELD® Mounting Medium Vector Laboratories, 
Burlingame, CA, USA 
ready-
to-use 
w/o 
 



